EGFR and lung carcinoma: ADCs using the T moiety–exatecan combination, such as those for EGFR‐del19/T790M/C797S triple mutation lung cancer, demonstrate prolonged antitumor effects in PDX models that accurately simulate challenging clinical scenarios.